Number of speakers (n=145), their characteristics, and types of COI
| Speakers who disclosed a non-financial COI | |
| Speakers with condition in question | 29 (20%) |
| Speakers taking drug in question | 12 (8.3%) |
| Speakers who disclosed a financial COI | |
| Travel and lodging | 29 (55.8%) |
| Paid consultant for pharmaceutical company | 7 (13.5%) |
| Organisation represented receives funding from pharmaceutical company | 6 (11.5%) |
| Paid investigator in clinical trials | 5 (9.6%) |
| Participated in drug trials+travel expenses | 3 (5.8%) |
| Owns stock in the company | 1 (<1%) |
| Disclosed COI but did not specify | 1 (<1%) |
| Speaker’s position on drug approval | |
| Positive | 71 (49%) |
| Negative | 34 (23.4%) |
| Neutral | 40 (27.6%) |
COI, conflicts of interest.